AllerGenis Begins Testing Patient Samples for Peanut Allergy Using Proprietary Epitope Mapping Technology

HATFIELD, PA - Business Wire

Data-driven food allergy diagnostics company, AllerGenis LLC, today announced its activities at the European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress 2020, being held virtually from June 6th through 8th. AllerGenis will have two presentations at the Congress, which are detailed below.


Thematic Poster Presentation: Repeated validation of a high-performing peanut allergy diagnostic on POISED trial subjects

  • Session Title: Food allergy

  • Session Number: TPS 11, #711

  • Presenter: Paul Kearney, Head of Product and Clinical Development, AllerGenis

Late Breaking Oral Abstract Presentation: Differences in epitome response in peanut-allergic subjects treated with different immunotherapy preparations

  • Session Title: Immunotherapy: from Bench to Bedside

  • Session Number: LB OAS 01, #1776

  • Presenter: Dianne Campbell, VP, Scientific and Medical Affairs, Australia and New Zealand, DBV Technologies


Both presentations will be available to conference registrants from EAACI’s website up to six months after the event.

About AllerGenis

Established in 2017 and located in Hatfield, PA, AllerGenis develops precision, data-driven diagnostics to help healthcare providers more accurately and safely diagnose, assess and monitor patients with food allergies. The company was founded out of a collaboration between Genisphere, provider of the 3DNA® platform for targeted drug delivery, and Hugh Sampson MD, of the Elliot and Roslyn Jaffe Food Allergy Institute of the Icahn School of Medicine at Mount Sinai. AllerGenis’ proprietary epitope mapping technology is based on immunological research by Dr. Sampson and leverages Genisphere’s expertise in improving sensitivity of diagnostic tests. AllerGenis is creating the largest food allergy knowledge base populated by individual patient epitope signatures derived from epitope mapping, clinical history, and patient-reported outcomes to gain clinical insights.

For more information, visit AllerGenis.com.

Contacts

For journalist enquiries please contact Azeem Zeekrya at azeem.zeekrya@hdmz.com or phone (312) 506-5244.

For investor enquiries please contact Jim Garner at jim.garner@allergenis.com or phone (401) 965-2499.

Samantha PennBusiness Wirepress release